Ivan Netuka

Ivan Netuka

Auto-generated profile, based on publicly available information

Ivan Netuka

Cardiovascular Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in JACC
Verified
Journal Article
Open access
INIvan Netuka
Ivan Netuka
PSPoornima Sood
Poornima Sood
YPYuriy Pya
Yuriy Pya
DZDaniel Zimpfer
Daniel Zimpfer
TKThomas Krabatsch
Thomas Krabatsch
JSJan D. Schmitto
Jan D. Schmitto
The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure. The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse. The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS. The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal. Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant. Fifty patients were enrolled at 10 centers. The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%). At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died. Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal. Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093). Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%). There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events. New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement. The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status. (HeartMate 3™ CE Mark Clinical Investigation Plan [HM3 CE Mark]; NCT02170363).

1 April 2019 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DGDaniel J. Goldstein
Daniel J. Goldstein
BMBart Meyns
Bart Meyns
RXRongbing Xie
Rongbing Xie
JCJennifer Cowger
Jennifer Cowger
SPStephen Pettit
Stephen Pettit
JKJames K. Kirklin
James K. Kirklin

1 May 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
INIvan Netuka
Ivan Netuka
PIPeter Ivák
Peter Ivák
ZTZuzana Tučanová
Zuzana Tučanová
SGStanislav Gregor
Stanislav Gregor
OSOndrej Szárszoi
Ondrej Szárszoi
MMMandeep R. Mehra
Mandeep R. Mehra

1 July 2016 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
INIvan Netuka
Ivan Netuka
TKTomas Kvasnicka
Tomas Kvasnicka
JKJan Kvasnička
Jan Kvasnička
IHIngrid Hrachovinová
Ingrid Hrachovinová
PIPeter Ivák
Peter Ivák
MMMandeep Mehra
Mandeep Mehra

1 September 2009 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
BOBohuslav Ostadal
Bohuslav Ostadal
INIvan Netuka
Ivan Netuka
JMJiri Maly
Jiri Maly
JBJosef Besik
Josef Besik
IOIvana Ostadalova
Ivana Ostadalova
This review summarizes some available information on gender differences of myocardial injury with particular attention to experimental approach. It has been observed that significant gender differences exist already in normal heart. They involve among others cardiac growth, contractile function, calcium metabolism and function of mitochondria. Differences, characteristic of the normal myocardium, generate the logical presumption of the different reaction of the male and female heart to various pathogenic factors. Most of the experimental studies confirm the clinical observations: increased resistance of the female heart to ischemia/reperfusion injury was shown in dogs, rats, mice and rabbits. Furthermore, gender differences in the ischemic tolerance of the adult myocardium can be influenced by interventions (e.g. hypoxia) imposed during the early phases of ontogenetic development. The already high tolerance of the adult female heart can be increased by adaptation to chronic hypoxia and ischemic preconditioning. It seems that the protective effect depends on age: it was absent in young, highly tolerant heart but it appeared with the decrease of natural resistance during aging. Both experimental and clinical studies have indicated that female gender influences favorably also the remodeling and the adaptive response to myocardial infarction. It follows from the data available that male and female heart differs significantly in many parameters under both physiological and pathological conditions. Detailed molecular and cellular mechanisms of these differences are still unknown; they involve genomic and non-genomic effects of sex steroid hormones, particularly the most frequently studied estrogens. The cardiovascular system is, however, influenced not only by estrogens but also by other sex hormones, e.g. androgens. Moreover, steroid hormone receptors do not act alone but interact with a broad array of co-regulatory proteins to alter transcription. The differences are so important that they deserve serious consideration in clinical practice in search for proper diagnostic and therapeutic procedures.

1 April 2019 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
YPYuryi Pya
Yuryi Pya
JMJiri Maly
Jiri Maly
MBMahabbat Bekbossynova
Mahabbat Bekbossynova
RSRoman Salov
Roman Salov
SSStephan Schueler
Stephan Schueler
INIvan Netuka
Ivan Netuka
The drive-line to power contemporary ventricular assist devices exiting the skin is associated with infection, and requires a holstered performance of the cardiac pump, which reduces overall quality of life. Attempts to eliminate the drive-line using transcutaneous energy transfer systems have been explored but have not succeeded in viable widespread application. The unique engineering of the coplanar energy transfer system is characterized by 2 large rings utilizing a coil-within-the-coil topology, ensuring robust resonance energy transfer while allowing for a substantial (>6 hours) unholstered circulatory support powered by an implantable battery source. Herein we report the first known human experience with this novel technology, coupled with a continuous-flow assist left ventricular assist device, in 2 consecutive patients evaluated with the primary end-point of system performance at 30 days post-implantation.